Kenneth R. Chien

Kenneth Randall Chien
NationalityAmerican
Alma mater
Known for
  • Research in the field of cardiovascular biotechnology and regenerative cardiovascular medicine
  • Co-founding Moderna
ParentLuther Chien (father)
AwardsPasarow Award (1996)
Scientific career
Fields
Institutions
  • Harvard University
  • Temple University
  • UC San Diego-Salk Institute
  • Massachusetts General Hospital
  • Karolinska Institute (Swedish: Karolinska Institutet)

Kenneth R. Chien (born 1951)[1] is an American doctor and medical scientist[2] who has been a research director at Karolinska Institute, in Stockholm, since 2013.[3] Chien has several papers with over 1,000 citations and a h-index of 132.[2] His area of expertise is cardiovascular science. His research into regenerative cardiovascular medicine, specifically while director of the Cardiovascular Program of the Harvard Stem Cell Institute,[4] led to his co-founding, in 2010, of ModeRNA Therapeutics.[5] In 2018, the company re-branded as Moderna, Inc.[6] Chien is a recipient of the Walter Bradford Cannon Award of the American Physiology Society and the Pasarow Award. He is a member of the Norwegian Academy of Science and Letters,[7] the Austrian Academy of Sciences,[8] and has received an honorary doctorate from the University of Edinburgh.[9]

  1. ^ "Utenlandske medlemmer" (in Norwegian). Norwegian Academy of Science and Letters. Archived from the original on 15 July 2007. Retrieved 27 December 2021.
  2. ^ a b "kenneth chien". scholar.google.com.
  3. ^ "| Karolinska Institutet". ki.se.
  4. ^ "Kenneth Chien". LinkedIn.
  5. ^ Xconomy: https://xconomy.com/boston/2012/12/06/moderna-40m-in-tow-hopes-to-reinvent-biotech-with-new-protein-drugs/
  6. ^ "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN.
  7. ^ "Group 7: Medical sciences". The Norwegian Academy of Science and Letters.
  8. ^ "Prof. KENNETH R. CHIEN, M.D. PH.D." Austrian Academy of Sciences.
  9. ^ "Professor Kenneth Chien". The University of Edinburgh.